The purpose of this study is to explore the impact of Ziprasidone HCl on the distribution of metabolic syndrome (MS) risk factors in a population of Bipolar patients presenting with glucose intolerance, dyslipidemia and/or elevated waist circumference associated with their current antipsychotic medication.
The trial was terminated prematurely on December 14, 2010, due to inability to recruit the planned number of subjects and shifting organizational priorities. The decision to terminate the trial was not based on any safety or efficacy concerns.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
13
Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40-160 mg total daily dose) for up to 1 year.
Foothills Medical Centre, Department of Psychiatry
Calgary, Alberta, Canada
Mental Health Centre for Research and Education
Calgary, Alberta, Canada
Dr. Alexander McIntyre Inc.
Penticton, British Columbia, Canada
Percentage of Participants Who Achieved a Reduction From Baseline of at Least 1 Risk Factor for Metabolic Syndrome (MS) at Week 52 or Premature Discontinuation
MS risks factors: elevated (el) waist circumference: ≥102 centimeters (cm) in men and ≥88 cm in women (Asian origin: ≥90 cm \[men\] and ≥80 cm \[women\]); el triglycerides: ≥1.7 millimoles per liter (mmol/L) (1≥50 milligrams per deciliter \[mg/dL\]); reduced high-density lipoprotein cholesterol (HDL-C): \<1.03 mmol/L (\<40 mg/dL) in men and \<1.3 mmol/L (\<50 mg/dL) in women; el fasting glucose: ≥5.6 mmol/L (≥100 mg/dL); and el systolic/diastolic blood pressure: systolic ≥130 millimeters of mercury (mmHg) and/or diastolic ≥85 mmHg. Responder = at least 1 less risk factor at endpoint than baseline.
Time frame: Week 52 or Early Termination
Mean Change From Baseline in the Number of Risk Factors of Metabolic Syndrome (MS)
MS risks factors: elevated waist circumference: ≥102 cm in men and ≥88 cm in women (Asian origin: ≥90 cm \[men\] and ≥80 cm \[women\]); elevated triglycerides: ≥1.7 mmol/L (1≥50 mg/dL); reduced HDL-C: \<1.03 mmol/L (\<40 mg/dL) in men and \<1.3 mmol/L (\<50 mg/dL) in women; elevated fasting glucose: ≥5.6 mmol/L (≥100 mg/dL); and elevated systolic/diastolic blood pressure: systolic blood pressure ≥130 mm Hg and/or diastolic blood pressure ≥85 mm Hg.
Time frame: Baseline, Week 52
Metabolic Syndrome (MS) Prevalence
Percentage of participants at each visit defined as having metabolic syndrome (MS) based on the National Cholesterol Education Program (NCEP) Adult Treatment Panel III. MS = 3 or more of 5 characteristics: abdominal obesity, hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol, high blood pressure, and high fasting glucose.
Time frame: Baseline through Week 52
Change From Baseline in the Percentage of Participants With Each Individual Metabolic Syndrome (MS) Risk Factor
MS risks factors: elevated waist circumference: ≥102 cm in men and ≥88 cm in women (Asian origin: ≥90 cm \[men\] and ≥80 cm \[women\]); elevated triglycerides: ≥1.7 mmol/L (1≥50 mg/dL); reduced HDL-C: \<1.03 mmol/L (\<40 mg/dL) in men and \<1.3 mmol/L (\<50 mg/dL) in women; elevated fasting glucose: ≥5.6 mmol/L (≥100 mg/dL); and elevated systolic/diastolic blood pressure: systolic blood pressure ≥130 mm Hg and/or diastolic blood pressure ≥85 mm Hg.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Country Club Plaza
Winnipeg, Manitoba, Canada
Edgeland Medical, Dr. Alla Kirshner Medical Corporation
Winnipeg, Manitoba, Canada
Capital, Health Authority, QE II Health Sciences Centre, Mood Disorder Clinic
Halifax, Nova Scotia, Canada
Office of Dr. A. K. Munshi
Sydney, Nova Scotia, Canada
Centre de recherche Fernand-Seguin de l'hopital Louis H. Lafontaine
Montreal, Quebec, Canada
Clinique St-Leonard
Montreal, Quebec, Canada
Diex Research Sherbrooke Inc.
Sherbrooke, Quebec, Canada
Time frame: Baseline through Week 52
Percentage of Participants With Individual Metabolic Syndrome (MS) Risk Factors
MS risks factors = elevated waist circumference: ≥102 cm in men and ≥88 cm in women (Asian origin: ≥90 cm \[men\] and ≥80 cm \[women\]); elevated triglycerides: ≥1.7 mmol/L (1≥50 mg/dL); reduced HDL-C: \<1.03 mmol/L (\<40 mg/dL) in men and \<1.3 mmol/L (\<50 mg/dL) in women; elevated fasting glucose: ≥5.6 mmol/L (≥100 mg/dL); and elevated systolic/diastolic blood pressure: systolic blood pressure ≥130 mm Hg and/or diastolic blood pressure ≥85 mm Hg.
Time frame: Baseline through Week 52
Change From Baseline in Individual Risk Factors of Metabolic Syndrome (MS): Elevated Waist Circumference
MS risk factor elevated waist circumference defined as ≥102 centimeters (cm) in men and ≥88 cm in women (Asian origin: ≥90 cm \[men\] and ≥80 cm \[women\]).
Time frame: Baseline, Week 4, Week 12, Week 52
Change From Baseline in Individual Risk Factors of Metabolic Syndrome (MS): Elevated Systolic/Diastolic Blood Pressure
MS risk factor elevated systolic/diastolic blood pressure defined as systolic blood pressure ≥130 millimeters of mercury (mm Hg) and/or diastolic blood pressure ≥85 mm Hg.
Time frame: Baseline, Week 4, Week 12, Week 52
Change From Baseline in Individual Risk Factors of Metabolic Syndrome (MS): Elevated Fasting Glucose
MS risk factor elevated fasting glucose defined as ≥5.6 millimoles per liter (mmol/L) (≥100 mg/dL).
Time frame: Baseline, Week 4, Week 12, Week 52
Change From Baseline in Individual Risk Factors of Metabolic Syndrome (MS): Reduced High-density Lipoprotein Cholesterol (HDL-C)
MS risk factor reduced HDL-C defined as \<1.03 millimoles per liter (mmol/L) (\<40 mg/dL) in men and \<1.3 mmol/L (\<50 mg/dL) in women.
Time frame: Baseline, Week 4, Week 12, Week 52
Change From Baseline in Individual Risk Factors of Metabolic Syndrome (MS): Elevated Triglycerides
MS risk factor elevated triglycerides defined as ≥1.7 millimoles per liter (mmol/L) (1≥50 mg/dL).
Time frame: Baseline, Week 4, Week 12, Week 52
Change From Baseline in Ten-year Coronary Heart Disease (CHD) Risk According to Framingham Scoring System
Framingham scoring system risk factors: age (risk points range: -9 to 16), cholesterol (risk points range: 0 to 13), HDL cholesterol (risk points range: -1 to 2), smoking (risk points range: 0 to 9), and systolic blood pressure (risk points range: 0 to 6); total risk points range \<0 to ≥25, higher score indicates higher 10 year risk (range \<1% to ≥30% 10 year risk).
Time frame: Baseline, Week 4, Week 52
Change From Baseline in Total Cholesterol and Low-density Lipoprotein (LDL) Cholesterol Levels
Time frame: Baseline, Week 52 or Early Termination
Change From Baseline in Weight
Time frame: Baseline, Week 4, Week 12, Week 52 or Early Termination
Change From Baseline in Body Mass Index (BMI)
Body mass index = weight in kilograms (kg) / height in meters (m)\^2 .
Time frame: Baseline, Week 4, Week 12, Week 52 or Early Termination
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
Time frame: Baseline, Week 52 or Early Termination
Change From Baseline in Insulin Levels
Time frame: Baseline, Week 52 or Early Termination
Change From Baseline in Corrected QT Interval (QTc): Fridericia's Heart Rate Correction Formula (QTcF)
QT interval is the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTc is the QT interval corrected for heart rate. Corrected QT interval using Fridericia's heart rate correction formula: QTcF = QT/RR\^1/3, where RR=RR interval in seconds.
Time frame: Baseline, Week 4, Week 52 or Early Termination
Change From Baseline in Apolipoprotein B (ApoB) Levels
Time frame: Baseline, Week 52 or Early Termination
Change From Baseline in Leptin
Time frame: Baseline, Week 52 or Early Termination
Change From Baseline in Physical Activity Index
Physical activity (exercise) score derived for each participant based on the frequency and intensity of physical activities: regular walking, recreational activity, cycling, and sporting activity. Six categories of total score: inactive (range: 0-2), occasional (range: 3-5), light (range: 6-8), moderate (range: 9-12), moderately vigorous (range: 13-20), and vigorous (≥21). Higher score = higher frequency and intensity of physical activity.
Time frame: Baseline, Week 28, Week 52 or Early Termination
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) - Total Score
Measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
Time frame: Baseline, Week 4, Week 12, Week 28, Week 52 or Early Termination
Change From Baseline in Young Mania Rating Scale (YMRS)
11-item scale that measures the severity of manic episodes from subject reported symptoms over previous 48 hours and clinical observation during interview. Four items (irritability, speech, thought content, disruptive-aggressive behaviour) are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining 7 items (elevated mood, increased motor activity-energy, sexual interest, sleep, language-thought disorder, appearance, insight) are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). YMRS total score range = 0 to 60.
Time frame: Baseline, Week 4, Week 12, Week 28, Week 52 or Early Termination
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Subscale
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.
Time frame: Baseline, Week 4, Week 12, Week 28, Week 52 or Early Termination
Clinical Global Impression - Improvement (CGI-I) Subscale Score
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.
Time frame: Week 52 or Early Termination
Change From Baseline in Drug Attitude Inventory (DAI)
DAI, a 10-item scale to assess how the attitude of schizophrenia participants toward their medications may affect compliance. Respondents indicate 'true' or 'false' for each item. An overall calculated score ranged from -10 to 10, where a positive score indicated a positive subjective response (compliant), a negative score indicated non-compliance. Change: score at observation minus score at baseline.
Time frame: Week 28, Week 52 or Early Termination
Change From Baseline in Social and Occupational Functioning Assessment Scale (SOFAS)
0-100 single score scale focusing exclusively on participant's level of social and occupational functioning; not directly influenced by overall severity of participant's psychological symptoms; higher score = higher level of functioning. 1 to 10 = persistent inability to maintain minimal personal hygiene; unable to function without harming self or others or without considerable external support; 91 to 100 = superior functioning in a wide range of activities.
Time frame: Baseline, Week 28, Week 52 or Early Termination
Change From Baseline in EuroQoL Index (EQ-I)
EQ-5D: subject rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Time frame: Baseline, Week 28, Week 52 or Early Termination
Change From Baseline in European Quality of Life (EuroQol) Visual Analogue Scale (EQ-5D VAS): Current Health State Score
EQ-5D: subject rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
Time frame: Baseline, Week 28, Week 52 or Early Termination
Change From Baseline in Impact of Weight on Quality of Life-Lite Version (IWQOL-Lite) Scale
31-item self report inventory to assess impact of weight on quality of life. Five subscales: physical functioning, self-esteem, sexual life, public distress, and work, with categories in each subscale scored 1 (no trouble or difficulty) to 5 (persistent trouble or difficulty). The rescaled IWQoL-Lite score is determined by the sum of scores on all 31 items and rescaling this sum to a 1 to 100 scoring with 0=the poorest and 100=the best quality of life.
Time frame: Baseline, Week 28, Week 52 or Early Termination
Number of Participants With Suicidal Tendencies (Columbian-Suicide Severity Rating Scale, [C-SSRS], Mapped to C-CASA [Columbia Classification Algorithm For Suicide Assessment])
C-SSRS is a participant rated questionnaire to assess suicidal ideation, suicidal behavior, actual attempts (yes or no responses), and intensity of ideation (rated 1=low severity to 5=high severity). Yes/No responses are mapped to Columbia Classification Algorithm of Suicide Assessment (C-CASA) categories: Completed suicide, suicide attempt, preparatory acts toward imminent suicidal behavior, suicidal ideation, and self-injurious behavior, or no suicidal intent. A participant could have a yes or no response in more than one category.
Time frame: Baseline, Week 1 through Week 52 or Early Termination